Adenovirus
A bifunctional ligand protein modifies adenoviral tropism
Published in Gene Therapy Weekly, April 3rd, 2003
According to a study from the United States, "in order to target recombinant adenovirus (AdV), we have developed a new strategy using a fusion ligand protein comprising coxsackievirus/adenovirus receptor (CAR), and the antibody Fc-binding domain from protein A in in vitro testing with this ligand shows that it blocks viral gene transduction and, when coupled with anti-ICAM-1 1gG, redirects AdV to endothelial cells that are induced to express ICAM-1."
"Because the protein A Fc-binding domain will bind to any immunoglobulin, the current strategy can be adapted to target a wide variety of...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
Source: Gene Therapy Weekly (2003-04-03)
More Articles from Gene Therapy Weekly
- Myocardial Ischemia
Insulin-like growth factor gene transfer rejuvenates the injured heart - Oncology
A suicide gene toxin halts slow-growing tumors - Gene Targets
RNA interference may be more potent than antisense RNA in human cancer cells - Gene Vectors
Chitosan powder complexes can deliver gene therapy to the lungs - Vector Development
Replicative retroviral vectors are advantageous for cancer gene therapy - Cancer Gene Therapy
Peptide fusion improves the efficacy of thymidine kinase suicide gene therapy - More from this issue of Gene Therapy Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
